# Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer

> **NCT01430585** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 14 (actual)

## Conditions studied

- Early Breast Cancer (Phase 2)
- Advanced Breast Cancer (Phase 1b)

## Interventions

- **DRUG:** PF-04691502
- **DRUG:** PF-04691502 in combination with Letrozole
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT01430585
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-03
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2014-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01430585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01430585, "Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01430585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*